Grade A
Rct
Rapamycin and Cellular Senescence: Insights from Clinical Trials
A phase 2 clinical trial examining the effects of low-dose rapamycin on markers of cellular senescence, immune function, and age-related biomarkers in healthy older adults.
Published 2024
19 views
[STUDY DETAILS]
- Study Type
- Rct
- Quality Grade
- A
- Publication Year
- 2024
- Category
- Longevity & Aging
Summary
This 12-month phase 2 RCT enrolled 150 healthy adults aged 65-80 to receive low-dose rapamycin (1mg/week) or placebo. The rapamycin group showed reduced senescent cell markers (p16INK4a, SA-beta-gal), improved vaccine response, and decreased inflammatory markers (IL-6, CRP).
Key Findings
1. p16INK4a expression reduced by 22% in treatment group
2. Influenza vaccine response improved by 38%
3. IL-6 levels decreased by 15%
4. Mild GI side effects in 18% of participants, resolved by month 3